Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease

[11] Huang S(2019)Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension Arch Osteoporos 39 278-823

[12] Smith S(2021)Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial J Bone Miner Metab 8 819-703

[13] Kendler D(2013)The relation between renal function and serum sclerostin in adult patients with CKD Clin J Am Soc Nephrol 6 700-1148

[14] Messina O(2011)Sclerostin: just one more player in renal bone disease? Clin J Am Soc Nephrol 8 1137-772

[15] Miller PD(1993)Vertebral fracture assessment using a semiquantitative technique J Bone Miner Res 53 766-59

[16] Klawansky S(2007)Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values Clin Chem 2011 1-405

[17] Komaroff E(2017)KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int Suppl 56 403-139

[18] Cavanaugh PF(2011)Japan Association of Chronic Kidney Disease Initiatives (J-CKDI) Japan Med Assoc J 167 133-3276

[19] Mitchell DY(2007)Renal function and risk of hip and vertebral fractures in older women Arch Intern Med 56 3271-255

[20] Gordon MJ(2017)Management of osteoporosis in chronic kidney disease Intern Med 99 248-undefined

[11] Huang S(2019)Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension Arch Osteoporos 39 278-823

[12] Smith S(2021)Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial J Bone Miner Metab 8 819-703

[13] Kendler D(2013)The relation between renal function and serum sclerostin in adult patients with CKD Clin J Am Soc Nephrol 6 700-1148

[14] Messina O(2011)Sclerostin: just one more player in renal bone disease? Clin J Am Soc Nephrol 8 1137-772

[15] Miller PD(1993)Vertebral fracture assessment using a semiquantitative technique J Bone Miner Res 53 766-59

[16] Klawansky S(2007)Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values Clin Chem 2011 1-405

[17] Komaroff E(2017)KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int Suppl 56 403-139

[18] Cavanaugh PF(2011)Japan Association of Chronic Kidney Disease Initiatives (J-CKDI) Japan Med Assoc J 167 133-3276

[19] Mitchell DY(2007)Renal function and risk of hip and vertebral fractures in older women Arch Intern Med 56 3271-255

[20] Gordon MJ(2017)Management of osteoporosis in chronic kidney disease Intern Med 99 248-undefined